tiprankstipranks
Advertisement
Advertisement
Glaukos Corp. Risk Profile in Flux as New 10‑Q Disclosures Replace 2025 10‑K, Heightening Uncertainty for Investors
PremiumCompany AnnouncementsGlaukos Corp. Risk Profile in Flux as New 10‑Q Disclosures Replace 2025 10‑K, Heightening Uncertainty for Investors
1M ago
Glaukos Corp. Earnings Call Signals Growth Momentum
Premium
Company Announcements
Glaukos Corp. Earnings Call Signals Growth Momentum
1M ago
Glaukos price target raised to $153 from $134 at Goldman Sachs
Premium
The Fly
Glaukos price target raised to $153 from $134 at Goldman Sachs
1M ago
Glaukos price target raised to $140 from $135 at Citi
PremiumThe FlyGlaukos price target raised to $140 from $135 at Citi
1M ago
Glaukos Reaffirmed as Buy on Strong Q1 Beat, Raised 2026 Revenue Outlook, and Billion-Dollar Peak Potential for iDose and Epioxa
Premium
Ratings
Glaukos Reaffirmed as Buy on Strong Q1 Beat, Raised 2026 Revenue Outlook, and Billion-Dollar Peak Potential for iDose and Epioxa
1M ago
Glaukos reports Q1 EPS (18c), consensus (28c)
Premium
The Fly
Glaukos reports Q1 EPS (18c), consensus (28c)
1M ago
William Blair med tech analyst holds an analyst/industry conference call
PremiumThe FlyWilliam Blair med tech analyst holds an analyst/industry conference call
2M ago
Glaukos price target raised to $135 from $125 at Citi
Premium
The Fly
Glaukos price target raised to $135 from $125 at Citi
2M ago
Seaport Research med technology analyst holds analyst/industry conference call
Premium
The Fly
Seaport Research med technology analyst holds analyst/industry conference call
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100